InvestorsHub Logo
Followers 35
Posts 6308
Boards Moderated 0
Alias Born 02/09/2015

Re: None

Friday, 01/15/2016 7:11:21 PM

Friday, January 15, 2016 7:11:21 PM

Post# of 403159
further Kevetrin ovarian phase 2 comparison- dosing started for the Aprea trial(PISSARO) on April 16 2014 with 4 trial site 1 in Belgium and 3 in the UK. So for ovarian we will be at least 2 years behind a p53 trial where they have have 4 sites to enroll patients in the trial.

It has been suggested by those who know a lot about p53 that Kevetrin is a better drug, but of course no one really knows
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News